Video

June 29, 2022

Dr. Rovner on adherence to AUA publication guidelines for SUI literature

Author(s):

Eric S. Rovner, MD, professor of Urology, Medical University of South Carolina (MUSC), discusses the abstract, “Revisiting adherence to the AUA publication guidelines for SUI literature,” which was presented at the 2022 AUA Annual Meeting.

Related Content

January 20th 2025

ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures

Hannah Clarke

Functional success was achieved in 58% of patients at 5-year follow-up.

$Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB$

March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff

“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.

December 23rd 2024

FDA approves vibegron for OAB symptoms in pharmacologically treated BPH

Hannah Clarke

The approval of vibegron is supported by data from the phase 3 COURAGE trial.

March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff

“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.

December 12th 2024

FDA greenlights pivotal trial of wearable bioelectronic device for OAB

Hannah Clarke

The primary aims for the EVANESCE-II trial are to confirm the safety of the FemPulse System and to establish noninferiority to first-line tolterodine.

November 4th 2024

iTNM may provide comparable safety, efficacy to SNM for OAB, UUI

Hannah Clarke

The UUI responder rate was 71.8% among those who received SNM and 71.3% among those who received iTNM.

Related Content

January 20th 2025

ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures

Hannah Clarke

Functional success was achieved in 58% of patients at 5-year follow-up.

$Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB$

March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff

“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.

December 23rd 2024

FDA approves vibegron for OAB symptoms in pharmacologically treated BPH

Hannah Clarke

The approval of vibegron is supported by data from the phase 3 COURAGE trial.

March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff

“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.

December 12th 2024

FDA greenlights pivotal trial of wearable bioelectronic device for OAB

Hannah Clarke

The primary aims for the EVANESCE-II trial are to confirm the safety of the FemPulse System and to establish noninferiority to first-line tolterodine.

November 4th 2024

iTNM may provide comparable safety, efficacy to SNM for OAB, UUI

Hannah Clarke

The UUI responder rate was 71.8% among those who received SNM and 71.3% among those who received iTNM.